Azhar Zahir
Internal Medicine · Las Cruces, NMNPI 1750465258
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.0% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 15.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $801 and has fallen 75.4% since, to $197 in 2025. Among internal medicine clinicians in NM with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $15.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$428
- AbbVie$339
- Pfizer$292
- AstraZeneca$272
- Novo Nordisk$253
- Sanofi-aventis U.S. LLC$189
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,77999%
- Education$281%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 25 | $428 |
| AbbVie(2 entities) | 21 | $339 |
| Pfizer | 19 | $292 |
| AstraZeneca | 17 | $272 |
| Novo Nordisk | 26 | $253 |
| Sanofi-aventis U.S. LLC | 11 | $189 |
| Lilly USA, LLC | 12 | $185 |
| Johnson & Johnson | 9 | $153 |
| Sanofi | 5 | $91 |
| Abbott | 4 | $84 |
| Amarin Pharma, Inc. | 4 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $55 |
| Novartis | 3 | $54 |
| E.r. Squibb & Sons, L.L.C. | 3 | $49 |
| Abiomed | 2 | $45 |
| Bioventus LLC | 2 | $36 |
| Alnylam Pharmaceuticals Inc. | 1 | $24 |
| Bayer | 1 | $19 |
| Esperion Therapeutics, Inc. | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $18 |
| Chiesi USA, Inc. | 1 | $18 |
| Astellas Pharma US Inc | 1 | $18 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Amgen | 1 | $15 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $12 |
How this compares
$2,806 in reported general payments places this provider in the 95th percentile of 578 internal medicine providers in New Mexico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 225 | $281,651 |
| EliquisApixaban | 214 | $181,858 |
| JardianceEmpagliflozin | 148 | $155,160 |
| ProliaDenosumab | 56 | $98,165 |
| FarxigaDapagliflozin Propanediol | 85 | $93,300 |
| JanuviaSitagliptin Phosphate | 49 | $60,305 |
| XifaxanRifaximin | 19 | $59,291 |
| MounjaroTirzepatide | 41 | $49,522 |
| TrulicityDulaglutide | 24 | $49,401 |
| XareltoRivaroxaban | 44 | $46,445 |
| Tresiba Flextouch U-200Insulin Degludec | 33 | $37,778 |
| RybelsusSemaglutide | 20 | $31,112 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 25 | $29,114 |
| Bydureon BciseExenatide Microspheres | 19 | $19,377 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $15,331 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $253 | $312,763245 claims |
| PfizerEliquis | $292 | $181,858214 claims |
| Boehringer IngelheimJardiance, Tradjenta | $18 | $166,997164 claims |
| AstraZenecaFarxiga, Symbicort | $272 | $108,631116 claims |
| Lilly USA, LLCMounjaro, Trulicity | $185 | $98,92365 claims |
| AmgenProlia | $15 | $98,16556 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $55 | $59,29119 claims |
| Johnson & JohnsonXarelto | $153 | $46,44544 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $428 | $42,10456 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $189 | $14,37439 claims |
| AbbVieSynthroid | $339 | $7,057108 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 578 internal medicine providers in New Mexico.
Other internal medicine in Las Cruces
- Ann MercerLas Cruces$6K
- Sangeeth PaiLas Cruces$4K
- Syed AhmedLas Cruces$3K
- Talha KhanLas Cruces$3K
- Jobin PhiliposeLas Cruces$2K
- Louis BeneventoLas Cruces$2K
- Edna JuarezLas Cruces$2K
- Edward LewieckiAlbuquerque$491K
- James AdairAlbuquerque$108K
- Gulshan ParasherAlbuquerque$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.